Afrezza® INHALE-1 Study in Pediatrics
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 319 participants.
Also called NCT04974528
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 319 participants
- Registry
-
NCT04974528
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT04974528. Randomized; no masking; primary purpose treatment. Start 2021-09-29 (actual); primary completion 2024-10-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Afrezza® INHALE-1 Study in Pediatrics
- Acronym
- INHALE-1
- Condition
- Diabetes Mellitus, Type 1
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Biological)
- Afrezza
- Intervention (Biological)
- Rapid-acting Insulin Analog
- Intervention (Biological)
- Basal Insulin
- Lead sponsor
- Mannkind Corporation
- Collaborator
- Jaeb Center for Health Research
Record details
- Record id
cardio:ct-nct04974528- Content hash
d6304d2a6299861afba4f201da43ebe0c021ce32d94b76de82d95ab887364b96